Nac (Acetylcysteine)

Acetylcysteine breaks disulfide bonds in mucus glycoproteins, reducing viscosity and improving clearance. It is also converted to cysteine, a precursor for glutathione, thereby restoring cellular antioxidant defenses and detoxifying harmful metabolites such as NAPQI in acetaminophen poisoning.

The appropriate dose of Nac is determined by the prescribing healthcare professional based on the specific indication, patient age, weight, renal and hepatic function, and local regulatory guidelines. Patients should follow the prescriber’s instructions exactly.

Data on acetylcysteine use in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under the guidance of a qualified healthcare provider.

To order Nac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other mucolytics such as carbocisteine, acetylcysteine has a dual role: it directly reduces mucus viscosity and also replenishes glutathione, offering antioxidant protection. This makes it useful not only for respiratory conditions but also for acetaminophen overdose and contrast‑induced nephropathy, where carbocisteine has no role.

Nac should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Nac is administered orally, typically as a tablet, capsule, or liquid preparation, depending on the product format supplied. The exact method of intake—such as with water, on an empty stomach, or with food—should follow the prescribing clinician’s directions.

The most serious adverse reactions to watch for are anaphylactoid responses (rash, wheezing, hypotension) and severe bronchospasm, which can be life‑threatening. Immediate medical attention is required if any signs of these reactions appear.

Nac is contraindicated in individuals with known hypersensitivity to acetylcysteine or any of its excipients. Patients with uncontrolled asthma or a history of severe bronchospasm should avoid oral use unless closely monitored by a healthcare professional.